» Articles » PMID: 17452812

Vasodilating Mechanisms of Levosimendan: Involvement of K+ Channels

Overview
Journal J Pharmacol Sci
Specialty Pharmacology
Date 2007 Apr 25
PMID 17452812
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Levosimendan, a novel agent developed for the treatment of acute and decompensated heart failure, exerts potent positive inotropic action and peripheral vasodilatory effects. The mechanism of vasodilation by levosimendan may involve reduction of Ca2+ sensitivity of contractile proteins in vascular smooth muscle, the lowering of intracellular free Ca2+, the potential inhibition of phosphodiesterase (PDE) III, and an opening of K+ channels. Although the importance and relative contribution of each of these mechanisms of vasorelaxation is unclear and may be different in various vessels and dependent on the dose of levosimendan, the important roles of K+-channel opening and Ca2+ desensitization in vascular smooth muscle are obvious, whereas the role of PDE inhibition remains to be defined. This review article briefly discusses the current research data on the mechanism of levosimendan-induced vasodilation with an emphasis on the types of the blood vessels and the K+ channels. It also summarizes the current experimental and clinical knowledge of the use of levosimedan in the treatment of heart failure.

Citing Articles

An In Vitro Investigation of the Antiproliferative and Antimetastatic Effects of Levosimendan: Potential Drug Repurposing for Cervical Cancer.

Schelz Z, Muddather H, Jaski F, Bozsity N, Zupko I Curr Issues Mol Biol. 2024; 46(7):6566-6579.

PMID: 39057033 PMC: 11275392. DOI: 10.3390/cimb46070391.


Effect of levosimendan on ventricular remodelling in patients with left ventricular systolic dysfunction: a meta-analysis.

Wang X, Zhao X, Wang X, Cao L, Lu B, Wang Z ESC Heart Fail. 2024; 11(3):1352-1376.

PMID: 38419326 PMC: 11098670. DOI: 10.1002/ehf2.14714.


Understanding the Clinical Use of Levosimendan and Perspectives on its Future in Oncology.

Ribeiro E, Vale N Biomolecules. 2023; 13(9).

PMID: 37759695 PMC: 10526140. DOI: 10.3390/biom13091296.


Levosimendan inhibits disulfide tau oligomerization and ameliorates tau pathology in Tau-BiFC mice.

Lim S, Shin S, Sung Y, Lee H, Kim K, Song J Exp Mol Med. 2023; 55(3):612-627.

PMID: 36914856 PMC: 10073126. DOI: 10.1038/s12276-023-00959-5.


Levosimendan Reverses Cardiac Malfunction and Cardiomyocyte Ferroptosis During Heart Failure with Preserved Ejection Fraction via Connexin 43 Signaling Activation.

Zhang L, Chen G, Tang R, Xiong Y, Pan Q, Jiang W Cardiovasc Drugs Ther. 2023; 38(4):705-718.

PMID: 36881213 DOI: 10.1007/s10557-023-07441-4.